Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 29 citing articles:

Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis
Lorenzo Onorato, Ilaria de Luca, Caterina Monari, et al.
Journal of Infection (2024) Vol. 88, Iss. 3, pp. 106113-106113
Open Access | Times Cited: 18
Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
Petros I. Rafailidis, Periklis Panagopoulos, Christos Koutserimpas, et al.
Antibiotics (2024) Vol. 13, Iss. 3, pp. 261-261
Open Access | Times Cited: 16
Antibiotic Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections in View of the Newly Developed β-Lactams: A Narrative Review of the Existing Evidence
Francesca Serapide, Maurizio Guastalegname, Sara Palma Gullì, et al.
Antibiotics (2024) Vol. 13, Iss. 6, pp. 506-506
Open Access | Times Cited: 12
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence
Marin H. Kollef, Hervé Dupont, David E. Greenberg, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106882-106882
Open Access | Times Cited: 21
Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis
Milo Gatti, Federica Cosentino, Maddalena Giannella, et al.
International Journal of Antimicrobial Agents (2023) Vol. 63, Iss. 2, pp. 107047-107047
Closed Access | Times Cited: 18
Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study
Alessandra Oliva, L Liguori, S. Covino, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 6, pp. 1149-1160
Open Access | Times Cited: 7
Antibiotic Treatment of Carbapenem-Resistant <em>Acinetobacter baumannii </em>Infections in View of the Newly Developed β-Lactams: A Narrative Review of the Existing Evidence
Francesca Serapide, Maurizio Guastalegname, Sara Palma Gullì, et al.
(2024)
Open Access | Times Cited: 6
Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii
Siqin Zhang, Lingfang Di, Qi Yan, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 6
An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms
Sara Domingues, Tiago Lima, María José Saavedra, et al.
Life (2023) Vol. 13, Iss. 7, pp. 1427-1427
Open Access | Times Cited: 16
Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii
Arta Karruli, Antonella Migliaccio, Spyros Pournaras, et al.
Antibiotics (2023) Vol. 12, Iss. 12, pp. 1729-1729
Open Access | Times Cited: 12
Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: New data from CREDIBLE-CR with an updated meta-analysis
Karan Gill, Takamichi Baba, Andrew I. Cooper
International Journal of Antimicrobial Agents (2024) Vol. 63, Iss. 6, pp. 107167-107167
Closed Access | Times Cited: 4
Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study
Daniele Roberto Giacobbe, Laura Labate, Chiara Russo Artimagnella, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 9, pp. 1929-1948
Open Access | Times Cited: 4
Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis
Yangyang Zhan, Wenchao Mao, Changyun Zhao, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Multidrug-Resistant Acinetobacter baumannii: Risk Factors for Mortality in a Tertiary Care Teaching Hospital
Kristina Černiauskienė, Astra Vitkauskienė
Tropical Medicine and Infectious Disease (2025) Vol. 10, Iss. 1, pp. 15-15
Open Access
Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline
Najma Arshad, Wael Azzam, Marya D. Zilberberg, et al.
Microorganisms (2025) Vol. 13, Iss. 2, pp. 356-356
Open Access
Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study
Julián Torre‐Cisneros, Benito Almirante, Carmen Martos, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2025)
Open Access
Are cefiderocol or sulbactam/durlobactam better than alternative best available treatment for infection by carbapenem-resistant A. baumannii? A systematic literature review
Stamatis Karakonstantis, Πέτρος Ιωάννου, Diamantis P. Kofteridis
Infection (2025)
Open Access
The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
Alessandro Russo, Francesca Serapide
Microorganisms (2025) Vol. 13, Iss. 4, pp. 829-829
Open Access
Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study
Cornelius J. Clancy, Oliver A Cornely, Stephen W. Marcella, et al.
Infection and Drug Resistance (2024) Vol. Volume 17, pp. 4427-4443
Open Access | Times Cited: 3
Co-Administration of High-Dose Nebulized Colistin for Acinetobacter baumannii Bacteremic Ventilator-Associated Pneumonia: Impact on Outcomes
Ioannis Andrianopoulos, Nikolaos Kazakos, Nikolaos Lagos, et al.
Antibiotics (2024) Vol. 13, Iss. 2, pp. 169-169
Open Access | Times Cited: 2
In reply to the Letter to the Editor regarding “Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis”
Milo Gatti, Federica Cosentino, Maddalena Giannella, et al.
International Journal of Antimicrobial Agents (2024) Vol. 63, Iss. 6, pp. 107168-107168
Closed Access | Times Cited: 2
Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature
David A. Butler, Nimish Patel, J. Nicholas O’Donnell, et al.
Journal of Antimicrobial Chemotherapy (2024)
Closed Access | Times Cited: 2
Risk factors and prognosis for the development of acute kidney injury in patients using colistin in the intensive care unit: A retrospective cohort study
Mustafa Deniz, Murat Alışık
Medicine (2024) Vol. 103, Iss. 2, pp. e36913-e36913
Open Access | Times Cited: 1
Cefiderocol in Difficult-to-Treat Nf-GNB in ICU Settings
Charles‐Hervé Vacheron, Anne Kaas, Jean‐Philippe Rasigade, et al.
Annals of Intensive Care (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint
Julien Massol, Aurélien Dinh, Katy Jeannot, et al.
Journal of Global Antimicrobial Resistance (2024) Vol. 38, pp. 140-145
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top